Elliot Staples III receives jail time after pleading guilty to manslaughter in the death of 3-year-old Jajuan Robinson, Jr., whom he was caring for when the child accessed an unsecured firearm.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
MTF Enterprises, a major operator of 43 Subway restaurants across four states, has filed for Chapter 11 bankruptcy, citing unsustainable debt burdens from merchant cash advance loans. The move highlights ongoing pressures within the franchise sector.
Investment firm Monument Capital Management has completely exited its position in Grand Canyon Education, selling 19,133 shares. The move comes as the education services provider navigates legal challenges and market underperformance.
Kalmar Oyj embarks on a strategic, long-term IT transformation with Tata Consultancy Services, building an AI-powered digital core to streamline operations, enhance equipment reliability, and solidify its service-led business model in the competitive port equipment sector.
NVIDIA has significantly revised its once-floated $100 billion investment plan for OpenAI, opting for a more measured commitment. The strategic shift underscores the chipmaker's focus on business discipline and diversifying its partnerships across the booming AI ecosystem, even as it remains central to OpenAI's operations.
STAAR Surgical's stock fell sharply after the ophthalmic device maker announced the appointment of interim co-CEOs, fueling investor uncertainty following the CEO's recent departure and a failed takeover attempt.
In a rare show of unity, Pennsylvania's political leaders from both parties are rallying behind the state's famed weather-predicting groundhog, pushing back against an animal rights group's call to replace the living animal with a digital projection.
A luxury car sale took an unexpected turn when a buyer casually wired a quarter-million dollars, revealing an unconventional fortune built not on Wall Street, but on trading cards. The incident highlights the blurring lines between niche hobbies and serious wealth generation.
Chinese regulators have greenlit the first wave of Nvidia's advanced H200 AI chip orders for major firms including Alibaba and ByteDance, marking a potential turning point for the chipmaker's access to a critical market and fueling optimism for its stock trajectory.
While 3M shares have significantly underperformed the broader market and its industrial peers over the past year, Wall Street maintains a cautiously optimistic stance, betting on the diversified giant's long-term recovery and earnings resilience.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
A routine traffic stop in Hazen, Arkansas, escalated into a perilous high-speed pursuit reaching 140 mph, culminating in a lone police chief facing down three suspects with a child in the vehicle. The dramatic confrontation, captured on Reelz's 'On Patrol: Live,' highlights the split-second decisions officers make when public safety and a child's welfare are on the line.
IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.
In a revealing interview, former NFL quarterback Tim Tebow recounts how coach Bill Belichick asked him to decline a seven-figure endorsement deal—only to be cut days later. Yet, a decade on, Tebow expresses admiration, not bitterness, toward the legendary coach.
